Calcipotriene and betamethasone dipropionate topical suspension, 0.005%/0.064%
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Calcipotriene and betamethasone dipropionate topical suspension, 0.005%/0.064%, covering 2018-12-21 to 2018-12-21. Get the full timeline:
Most recent: Clinical Trial Update: To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis [Phase 3]